Lupin Q1 FY27 Earnings Call — Analysis (NSE: LUPIN)
Lupin posts record Q1FY27 revenue of ₹8,277 Cr and EBITDA of ₹2,464 Cr, but guides for a material step-down in U.S. sales from Q2 due to new competition in Tolvaptan and Mirabegron.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 EBITDA (excl. forex & other income) ₹2,464 Cr ( +50% YoY ) . New guidance — FY27 u.s. business revenue fy27 USD 1.1 billion to USD 1.2 billion . New story: Complex generics and biosimilars pipeline as gr… .
Results
Revenue ₹8,277 Cr +32% YoY; EBITDA ₹2,464 Cr +50% YoY; gross margin 74.6% (+330bps YoY); U.S. sales $366M +30% constant currency; India formulations 13.9% YoY; net cash ₹2,831 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Revenue from Operations | ₹8,277 Cr | +32% | yoy · Q1FY27 |
| EBITDA (excl. forex & other income) | ₹2,464 Cr | +50% | yoy · Q1FY27 |
| EBITDA Margin | 30% | +340bps | yoy · Q1FY27 |
| Gross Margin | 74.6% | +330bps | yoy · Q1FY27 |
| U.S. Sales | $366 million | +30% constant currency | yoy · Q1FY27 · constant currency |
| India Formulations Revenue | ₹2,380 Cr | +13.9% | yoy · Q1FY27 |
| India Core Prescription Growth | 15.1% | yoy · Q1FY27 · 1.1x IPM growth (IPM 13.5%) | |
| Other Developed Markets Revenue | ₹1,149 Cr | +48% | yoy · Q1FY27 |
| Emerging Markets Revenue | ₹990 Cr | +52% | yoy · Q1FY27 |
| R&D Spend | ₹608 Cr | point_in_time · Q1FY27 · 7.4% of sales vs 8.1% Q1FY26 | |
| Net Cash | ₹2,831 Cr | point_in_time · Q1FY27 · 30 June 2026 | |
| Net Working Capital Days | 90 days | none · Q1FY27 · vs 87 days at 31 Mar 2026 | |
| ROCE | 29.5% | point_in_time · Q1FY27 · vs 28.4% at FY26-end |
Guidance
FY27 consolidated revenue growth guided high single-digit, EBITDA margins ~25%, U.S. revenue $1.1-1.2 billion, R&D ~8% of sales, effective tax rate 27-28%.
What management committed to
- Full-year FY27 U.S. business revenue will be in the range of USD 1.1 billion to USD 1.2 billion. — USD 1.1 billion to USD 1.2 billion, FY27
- Consolidated Lupin revenue growth for FY27 will be high single-digit. — high single-digit, FY27
- FY27 EBITDA margin will be around 25% (management indicated 24-25% range). — around 25%, FY27
- FY27 R&D spend will be around 8% of sales. — around 8%, FY27
- FY27 effective tax rate will be in the region of 27-28%. — 27-28%, FY27
- For Q2FY27 and Q3FY27, U.S. quarterly revenue will be between USD 250 million and USD 280 million. — USD 250 million to USD 280 million, Q2FY27 and Q3FY27
- India formulations business will continue to outperform IPM by 1.2x to 1.3x. — 1.2x to 1.3x, FY27
- Chronic share of India portfolio will increase to 70% in the next five years. — 70%, FY31
- Novel proprietary products will contribute one-third of India revenues within a 10-year timeframe. — one-third, FY36
- Biosimilars revenue across U.S. and Europe will ramp to a couple of hundred million dollars scale in the next three years. — a couple of hundred million dollars scale, FY30
- U.S. business will revert to a growth trajectory from FY28 onwards. — FY28
- [Lupin] will launch Pegfilgrastim in H2FY27 and it will contribute nicely. — FY27
Key themes
Record quarter tempered by U.S. competition headwinds and pipeline-driven recovery from FY28.
How the narrative shifted
- U.S. competition headwinds after record Q1: Management expects significant step-down in U.S. revenue from Q2 due to competitive entries in Tolvaptan and continued Mirabegron pressure, framing it as a short-term reset before a pipeline-driven recovery.
- Complex generics and biosimilars pipeline as growth engine: Management highlights a rich pipeline of 50+ products, respiratory MDIs/DPIs, injectables, and biosimilars, positioning it as the driver for U.S. growth resumption from FY28 and doubling complex product share.
- India branded business outperformance and innovation pivot: India formulations consistently outgrows IPM, chronic share rising, and a 10-year vision to shift one-third of revenues to novel proprietary products is introduced, signaling a long-term up-tiering of the portfolio.
- Europe and Emerging Markets as diversified growth levers: Management emphasizes 'under-indexed in Europe' and strong traction in Brazil, SA, Philippines, with biosimilars, complex generics, and specialty acquisitions like VISUfarma to sustain 10-20% growth.
- Adjacencies margin drag tapering over time: CFO quantifies the EBITDA drag from loss-making adjacencies at 1-1.5% and flags diagnostics reaching breakeven next year, framing it as a temporary overhang.
- Regulatory compliance gains provide supply chain confidence: VAI classification for Ankleshwar and Somerset and ongoing Pithampur remediation are used to signal a clean compliance posture, which underpins the ability to launch complex products from those sites.
Operational commentary
- U.S. quarterly revenue expected to step down to $250-280M in Q2-Q3 due to new entrants (Apotex, Teva) in Tolvaptan and increased competition in Mirabegron; full-year FY27 U.S. guidance $1.1-1.2B.
- U.S. pipeline: 50+ launches over next 3 years including 10 exclusive FTFs, 5 biosimilars, 2-3 505(b)(2)s; Pegfilgrastim (H2FY27), Dalbavancin 505(b)(2), Fluticasone nasal spray, Raltegravir FTF, Sugammadex, Epinephrine, Eribulin injection among near-term launches.
- India core Rx growth 15.1%, outperforming IPM by 1.1x; chronic share 67% (target 70% in 5 years); Diabetes segment +31.8% YoY, Semaglutide injection launched; vial and oral Semaglutide expected H2FY27; targeting 1.2-1.3x IPM outperformance.
- Other Developed Markets (Europe, Canada, Australia) +48% YoY with Europe +83%; consolidation of VISUfarma; strategic push with complex generics, biosimilars, and specialty; Europe growth expected 10-20% over next couple of years.
- Emerging Markets +52% YoY, Brazil +117% local currency driven by Dapagliflozin and Empagliflozin; Semaglutide launch planned in South Africa.
- Respiratory pipeline progress: SpiriRespimat filing on track for FY27; positive PK on Breo Ellipta; multiple MDI filings this year; green propellant Luforbec filed in Europe; leveraging device/platform learnings to accelerate filings.
- Compliance: EIRs with VAI status received for Ankleshwar and Somerset; Pithampur Unit II remediation ongoing.
- Adjacencies (diagnostics, digital, OTC, CDMO) currently loss-making, dragging EBITDA margins by ~1-1.5%; diagnostics expected to break even in FY28.
Analyst Q&A
Q. Clarification that U.S. growth resumption from FY28 will be on the FY27 base of $1.1-1.2 billion.
Yes, over the FY27 base.
Q. Why does U.S. quarterly revenue drop to ~$250-280M from Q2 despite strong Q1?
In Q1 no additional Tolvaptan competition; from Q2 Apotex and Teva enter, plus new entrant possibly in September; Mirabegron full-quarter impact; pricing and share erosion expected.
Q. Will Lupin be able to defend Tolvaptan market share after new entrants?
Expect market share tail to be longer due to specialty pharmacy/REMS, but will give some share to additional entrants.
Q. Potential size of Apixaban 505(b)(2) and its differentiation versus innovator.
Still sizing the opportunity; targeted approach to select channels; on differentiation, will share closer to launch date.
Q. Cumulative market size of the U.S. pipeline of 50 FTFs, 21 exclusive ones over 3-5 years.
Will get back to you offline to discuss overall brand revenues and limited-competition products.
Q. Rough size of Spiriva Respimat market vs DPI.
We'll get back to you with that; I don't have the exact numbers.
Q. How much are adjacencies dragging EBITDA margins?
Overall about 1-1.5%; diagnostics expected to break even next year; other businesses evolving well.
Research and educational content only. Not investment advice.